Sphere Fluidics Enhances Capabilities of its Cyto-Mine System
The new design improves system performance, reliability, and stability, while an update to the software provides a better user experience, reduces user-instrument interaction, and allows for more robust data analysis.
Sphere Fluidics has enhanced the capabilities and performance of its Cyto-Mine System, an automated platform that combines single cell screening, sorting, dispensing, imaging, and clone verification.
The new design improves system performance, reliability, and stability, while an update to the software provides a better user experience, reduces user-instrument interaction, and allows for more robust data analysis, Sphere Fluidics said in a May 17, 2021 company press release. The updated instrument also works to simplify antibody discovery, cell-line development, cell therapy, and synthetic biology workflows.
“The new design is the culmination of 18 months' hard work by our R&D team. Due to the deployment of these latest improvements, researchers are now able to perform even faster selective screening of single cells to find rare lead candidates,” said Marian Rehak, vice-president of Research and Development at Sphere Fluidics, in the press release. “Although, principally designed for antibody discovery and cell line development, the platform is very flexible and has now been demonstrated to be useful in a wide variety of application areas.”
“The new Cyto-Mine design not only unlocks increased functionality for scientists but is also faster to manufacture, commission, and service,” added Rob Treanor, operations director at Sphere Fluidics, in the press release. “A new user can learn how to run our user-friendly software within a single working day. We are helping our users to simplify their workflows with the added operational benefit of enhancing our service and support capacity.”
Source: Sphere Fluidics
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
